LEADER 02373nam  2200409z- 450 
001 9910220059703321
005 20210211
035   $a(CKB)3800000000216181
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/50258
035   $a(oapen)doab50258
035   $a(EXLCZ)993800000000216181
100   $a20202102d2016      |y         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aInhibiting PARP as a Strategic Target in Cancer
210   $cFrontiers Media SA$d2016
215   $a1 online resource (97 p.)
225 1 $aFrontiers Research Topics
311 08$a2-88919-955-X 
330   $aPoly-ADP ribose polymerase (PARP) proteins are critical mediators of DNA repair. Many traditional anti-cancer chemotherapy agents overwhelm a cell's ability to repair DNA damage in order to kill proliferating malignant cells. Recent evidence suggests that cancers within and across tissue types have specific defects in DNA repair pathways, and that these defects may predispose for sensitivity and resistance to various classes of cytotoxic agents. Breast, ovarian and other cancers develop in the setting of inherited DNA repair deficiency, and these cancers may be more sensitive to cytotoxic agents that induce DNA strand breaks, as well as to inhibitors of PARP activity. A series of recent clinical trials has tested whether PARP inhibitors can achieve synthetic lethality in hereditary DNA repair-deficient tumors. At the current time, mutation of BRCA serves as a potential, but not comprehensive, biomarker to predict response to PARP inhibitor therapy. Mechanisms of resistance to PARP inhibitors are only recently being uncovered. Future studies seek to identify sporadic cancers that harbor genomic instability rendering susceptibility to PARP inhibitors that compound lethal DNA damage.
606   $aMedicine$2bicssc
610   $aCancer
610   $acombination therapy
610   $aDNA Damage
610   $aDNA reapir
610   $aHomologous Recombination
610   $aPARP inhibitor
615  7$aMedicine
700   $aKristin Zorn$4auth$01311554
702   $aChristina Annunziata$4auth
906   $aBOOK
912   $a9910220059703321
996   $aInhibiting PARP as a Strategic Target in Cancer$93030415
997   $aUNINA